Tempest Therapeutics, Inc.
TPST
$0.91
-$0.08-7.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.42M | 12.89M | 10.77M | 10.41M | 10.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.46M | 17.98M | 23.38M | 33.22M | 40.17M |
| Operating Income | -18.46M | -17.98M | -23.38M | -33.22M | -40.17M |
| Income Before Tax | -40.47M | -43.10M | -26.26M | -36.05M | -43.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.47 | -43.10 | -26.26 | -36.05 | -43.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.47M | -43.10M | -26.26M | -36.05M | -43.10M |
| EBIT | -18.46M | -17.98M | -23.38M | -33.22M | -40.17M |
| EBITDA | -18.21M | -17.72M | -23.11M | -32.97M | -39.89M |
| EPS Basic | -4.49 | -6.21 | -6.84 | -10.40 | -14.93 |
| Normalized Basic EPS | -1.54 | -2.09 | -3.75 | -5.97 | -8.80 |
| EPS Diluted | -4.49 | -6.21 | -6.84 | -10.40 | -14.93 |
| Normalized Diluted EPS | -1.54 | -2.09 | -3.75 | -5.97 | -8.80 |
| Average Basic Shares Outstanding | 35.50M | 24.08M | 16.59M | 14.83M | 12.38M |
| Average Diluted Shares Outstanding | 35.50M | 24.08M | 16.59M | 14.83M | 12.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |